Mr. Jones will focus on the commercialization of EyePoint’s two FDA- approved, commercially launched eye products.
Dr. Saim will be responsible for clinical development, pharmaceutical sciences and manufacturing and operations of EyePoint’s ocular treatments.
“The launches of our two ophthalmology products have been met with strong interest from both patients and treating physicians for these debilitating eye diseases,” Nancy Lurker, president and CEO of EyePoint Pharmaceuticals said in a news release. “We look forward to leveraging Scott and Said’s respective expertise to drive growth of our market share.”
More articles on supply chain:
ASC supply chain tip of the day: Track trends
IU Health distribution center plans to deliver to ASCs
ASC supply chain tip of the day: Find effective partners
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.